# Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors

> **NCT03552406** · PHASE1 · UNKNOWN · sponsor: **ISU Abxis Co., Ltd.** · enrollment: 33 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **BIOLOGICAL:** ISU104
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT03552406
- **Lead sponsor:** ISU Abxis Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04-27
- **Primary completion:** 2020-10-19
- **Final completion:** 2021-12-31
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2021-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03552406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03552406, "Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03552406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*